Latest BioAge Labs News & Updates

See the latest news and media coverage for BioAge Labs. We track all announcements, press releases, and industry mentions in real time, all in one place.

BioAge Labs

Biotechnology company developing therapies for cardiometabolic diseases

bioagelabs.com

Headquarters: Emeryville, United States
Founded year: 2015
Company type: Public company
Number of employees: 100–200
Industry: Pharmaceuticals

Last updated Today

Latest news about BioAge Labs

In short: BioAge Labs launched Phase 2 trials for its NLRP3 inhibitor BGE-102 and secured major financing to support operations through 2029.

Company announcements

September 8 BioAge Labs

BioAge Labs begins Phase 2 BGE-102 diabetic eye trial

The company doses the first participant in a randomized study evaluating once-daily oral BGE-102 as monotherapy and alongside anti-VEGF therapy, with top-line data expected by late 2027.

August 5 BioAge Labs

BioAge Labs reports Q2 2026 results and BGE-102 progress

First participant dosed in Phase 2 QUELL-CV; topline data expected in H2 2026, with Q2 net loss of $26.1 million.

May 8 BioAge Labs

BioAge Labs reports Q1 2026 financial results

Positive Phase 1 data for BGE-102 shown. Phase 2 trials planned for mid-2026. $132.3M raised via offering. Net loss $22.3M.

April 21 BioAge Labs

BioAge reports positive Phase 1 data for BGE-102

BGE-102 achieves ≥85% median hsCRP reductions at 60 mg and 120 mg doses in obese participants. Well tolerated. Phase 2 trials in cardiovascular risk and DME planned for mid-2026.

Media coverage

August 11 American Banking News

Renaissance Technologies LLC Buys 120,188 Shares of BioAge Labs, Inc. $BIOA - American Market News

Renaissance Technologies LLC boosted its stake in shares of BioAge Labs, Inc. (NASDAQ:BIOA – Free Report) by 653.2% in the 1st quarter, according to its...

August 5 Markets Insider

BioAge Labs Reports Second Quarter 2026 Financial Results and Provides Business Updates

CV, a Phase 2 dose-ranging proof-of-concept trial of BGE-102 measuring inflammatory and cardiometabolic biomarkers; topline data anticipated in the second half of 2026 QUELL-DME, Phase...

August 3 Seeking Alpha

BioAge Labs posts partial recovery after deep selloff, rises 19%

(BIOA) rebounds after a 64% plunge tied to Novo's ZEUS trial failure—see key metrics, NLRP3 read-through risk, and what to watch next.

July 31 FinanzNachrichten.de

Aktien»Nachrichten»AXT AKTIE»Morning Market Movers: Replimune Group, BioAge Labs, T3 Defense, AXT, Inc. See Big Swings

BEIJING (dpa-AFX) - At 8:15 a.m. ET on Friday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities...

Never miss news about BioAge Labs

Track BioAge Labs and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

BioAge Labs competitors & trending companies

Browse news for competitors to BioAge Labs and other trending companies.